Andy Perlman

Director at Arcus Biosciences

Dr. Perlman has been a long-time leader in the biotechnology field. Dr. Perlman served as Senior Director of Clinical Research at Genentech contributing to their early success, including playing a key role in the development, FDA approval and marketing of Nutropin® (somatropin). He was one of the first hires at Tularik, with a broad array of responsibilities that early on included clinical trial design and implementation, ultimately expanding to include key roles in Tularik’s business development, investor relations and financing activities, culminating with Tularik’s acquisition by Amgen in 2004. Dr. Perlman’s experience also included serving as CEO of Affymax. He is currently Managing Director and Head of non-clinical Development of X-37, LLC, an artificial intelligence-enabled drug discovery company, as well as the Chief Medical Officer and Managing Director of Velocity Pharmaceutical Development. Dr. Perlman earned his M.D. and Ph.D. degrees from New York University, and carried out post-doctoral research in the laboratory of Nobel Laureate Professor Eric Kandel. He completed his post-graduate clinical training at NYU and Stanford School of Medicine.


Org chart

This person is not in the org chart


Teams

This person is not in any teams


Offices

This person is not in any offices


Arcus Biosciences

3 followers

Arcus Biosciences is a company creating new cancer therapeutics through the utilization of emerging insights in immunology. Arcus was formed in 2015 by a group of researchers from the biotechnology and pharmaceutical industries.


Industries

Employees

201-500

Links